Yunfei Chen, Yanmei Xu, Ying Chi, Ting Sun, Yuchen Gao, Xueqing Dou, Zhibo Han, Feng Xue, Huiyuan Li, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Mankai Ju, Xinyue Dai, Wentian Wang, Yueshen Ma, Zhen Song, Jundong Gu, Wei Gong, Renchi Yang, Lei Zhang
Patients with refractory immune thrombocytopenia (ITP) frequently encounter substantial bleeding risks and demonstrate limited responsiveness to existing therapies. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) present a promising alternative, capitalizing on their low immunogenicity and potent immunomodulatory effects for treating diverse autoimmune disorders. This prospective phase I trial enrolled eighteen eligible patients to explore the safety and efficacy of UC-MSCs in treating refractory ITP...
April 23, 2024: Signal Transduction and Targeted Therapy